Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2002 Jul;94(7):549–560.

Preventing diabetes-related morbidity and mortality in the primary care setting.

Samuel Dagogo-Jack 1
PMCID: PMC2594314  PMID: 12126280

Abstract

Diabetes is the leading cause of blindness, end-stage renal failure, non-traumatic limb amputations, and cardiovascular morbidity and mortality. The vast majority of patients with diabetes receive routine care from primary care providers who are not endocrinologists. Primary care providers, including internists, family practice physicians, and physician extenders with advanced skills, face the important task of implementing standards of care recommendations for persons with diabetes. These recommendations draw upon an emerging body of compelling evidence regarding the prevention and management diabetes and its complications. The challenge of diabetes must be tackled on three fronts: Primary prevention, secondary prevention (of diabetes complications), and tertiary prevention (of morbidity and mortality from established complications). There is now abundant evidence that type 2 diabetes, which accounts for greater than 90% of diabetes world-wide, is preventable. Moreover, the complications of diabetes are preventable by a policy of tight glycemic control and comprehensive risk reduction. Even after complications have set in, intensive glucose control dramatically reduces the risk of progression of complications. The challenge, therefore, is the identification of strategies that enable translation of existing scientific data to pragmatic benefits. This article proposes 10 strategies for preventing or reducing diabetes-related morbidity and mortality at the primary care level. These strategies include provider education; patient empowerment through promotion of lifestyle and self-care practices; surveillance for microvascular complications; cardiovascular risk reduction; efficient use of medications; goal setting; and stratification of patients and triaging of those with poor glycemic control for more intensive management.

Full text

PDF
559

Images in this article

555Figure 1
on p.555

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyle P. J., Schwartz N. S., Shah S. D., Clutter W. E., Cryer P. E. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med. 1988 Jun 9;318(23):1487–1492. doi: 10.1056/NEJM198806093182302. [DOI] [PubMed] [Google Scholar]
  2. Brancati F. L., Kao W. H., Folsom A. R., Watson R. L., Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000 May 3;283(17):2253–2259. doi: 10.1001/jama.283.17.2253. [DOI] [PubMed] [Google Scholar]
  3. Burke J. P., Williams K., Gaskill S. P., Hazuda H. P., Haffner S. M., Stern M. P. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999 Jul 12;159(13):1450–1456. doi: 10.1001/archinte.159.13.1450. [DOI] [PubMed] [Google Scholar]
  4. Dagogo-Jack S., Santiago J. V. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997 Sep 8;157(16):1802–1817. [PubMed] [Google Scholar]
  5. Gilmer T. P., O'Connor P. J., Manning W. G., Rush W. A. The cost to health plans of poor glycemic control. Diabetes Care. 1997 Dec;20(12):1847–1853. doi: 10.2337/diacare.20.12.1847. [DOI] [PubMed] [Google Scholar]
  6. Harris M. I., Eastman R. C., Cowie C. C., Flegal K. M., Eberhardt M. S. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999 Mar;22(3):403–408. doi: 10.2337/diacare.22.3.403. [DOI] [PubMed] [Google Scholar]
  7. Harris M. I. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care. 2001 Mar;24(3):454–459. doi: 10.2337/diacare.24.3.454. [DOI] [PubMed] [Google Scholar]
  8. Jencks S. F., Cuerdon T., Burwen D. R., Fleming B., Houck P. M., Kussmaul A. E., Nilasena D. S., Ordin D. L., Arday D. R. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. JAMA. 2000 Oct 4;284(13):1670–1676. doi: 10.1001/jama.284.13.1670. [DOI] [PubMed] [Google Scholar]
  9. Lawler F. H., Viviani N. Patient and physician perspectives regarding treatment of diabetes: compliance with practice guidelines. J Fam Pract. 1997 Apr;44(4):369–373. [PubMed] [Google Scholar]
  10. Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456–1462. doi: 10.1056/NEJM199311113292004. [DOI] [PubMed] [Google Scholar]
  11. Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851–860. doi: 10.1056/NEJMoa011303. [DOI] [PubMed] [Google Scholar]
  12. Lorenz R. A., Bubb J., Davis D., Jacobson A., Jannasch K., Kramer J., Lipps J., Schlundt D. Changing behavior. Practical lessons from the diabetes control and complications trial. Diabetes Care. 1996 Jun;19(6):648–652. doi: 10.2337/diacare.19.6.648. [DOI] [PubMed] [Google Scholar]
  13. Lowe L. P., Liu K., Greenland P., Metzger B. E., Dyer A. R., Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care. 1997 Feb;20(2):163–169. doi: 10.2337/diacare.20.2.163. [DOI] [PubMed] [Google Scholar]
  14. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ. 1997 May 24;314(7093):1512–1515. doi: 10.1136/bmj.314.7093.1512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mokdad A. H., Ford E. S., Bowman B. A., Nelson D. E., Engelgau M. M., Vinicor F., Marks J. S. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000 Sep;23(9):1278–1283. doi: 10.2337/diacare.23.9.1278. [DOI] [PubMed] [Google Scholar]
  16. Murphy M. B., Kitabchi A. E. Management of type 2 diabetes mellitus. Tenn Med. 2000 Nov;93(11):398–402. [PubMed] [Google Scholar]
  17. Musey V. C., Lee J. K., Crawford R., Klatka M. A., McAdams D., Phillips L. S. Diabetes in urban African-Americans. I. Cessation of insulin therapy is the major precipitating cause of diabetic ketoacidosis. Diabetes Care. 1995 Apr;18(4):483–489. doi: 10.2337/diacare.18.4.483. [DOI] [PubMed] [Google Scholar]
  18. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 May;28(2):103–117. doi: 10.1016/0168-8227(95)01064-k. [DOI] [PubMed] [Google Scholar]
  19. Pan X. R., Li G. W., Hu Y. H., Wang J. X., Yang W. Y., An Z. X., Hu Z. X., Lin J., Xiao J. Z., Cao H. B. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537–544. doi: 10.2337/diacare.20.4.537. [DOI] [PubMed] [Google Scholar]
  20. Peters A. L., Legorreta A. P., Ossorio R. C., Davidson M. B. Quality of outpatient care provided to diabetic patients. A health maintenance organization experience. Diabetes Care. 1996 Jun;19(6):601–606. doi: 10.2337/diacare.19.6.601. [DOI] [PubMed] [Google Scholar]
  21. Sprick A. N., Simoes E. J., McKeage C. B., Chang J. C. Diabetes-related deaths in Missouri 1989-1994. Mo Med. 1998 Jan;95(1):21–25. [PubMed] [Google Scholar]
  22. Stratton I. M., Adler A. I., Neil H. A., Matthews D. R., Manley S. E., Cull C. A., Hadden D., Turner R. C., Holman R. R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000 Aug 12;321(7258):405–412. doi: 10.1136/bmj.321.7258.405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tuomilehto J., Lindström J., Eriksson J. G., Valle T. T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343–1350. doi: 10.1056/NEJM200105033441801. [DOI] [PubMed] [Google Scholar]
  24. Wisdom K., Fryzek J. P., Havstad S. L., Anderson R. M., Dreiling M. C., Tilley B. C. Comparison of laboratory test frequency and test results between African-Americans and Caucasians with diabetes: opportunity for improvement. Findings from a large urban health maintenance organization. Diabetes Care. 1997 Jun;20(6):971–977. doi: 10.2337/diacare.20.6.971. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES